This post is presented by our media partner Psychedelic News Wire
View the original article here.
A small clinical trial involving military veterans suggests that a psychedelic called ibogaine has the potential to treat traumatic brain injury (TBI) symptoms such as depression and post-traumatic stress disorder (PTSD). The Stanford University study found that the lesser-known psychedelic reduced depression and PTSD symptoms by more than 80% in veterans with TBIs.
While the past few years have seen a surge of psychedelic-related studies and clinical trials, most of them have focused on classic psychedelics such as psilocybin (magic mushrooms), MDMA and LSD. These studies found that these popular psychedelics can be effective at treating the symptoms of various mental ailments, especially when they are combined with traditional talk therapy.
The recent study now adds ibogaine to the list of psychedelics that have the potential to treat debilitating mental disorders, including post-traumatic stress disorder and depression. Study coauthor and Stanford University neuroscientist Nolan Williams says that ibogaine seems to deliver a “broad, dramatic and consistent effect.”
The psychedelic is made from the bark of a central African shrub called Tabernanthe iboga and was traditionally used for ceremonial purposes.
According to Maria Steenkamp from the NYU Grossman School of Medicine, scientists have avoided researching the psychedelic for uses other than opioid dependence and withdrawal because it can cause fatal heartbeat irregularities and is strictly regulated in many nations. However, with more people failing to respond to conventional mental-health treatments such as therapy and antidepressants, Steenkamp says we “desperately need” new medical interventions.
Williams and his research team followed 30 U.S. veterans who went to a facility in Mexico where they purchased and took ibogaine alongside a magnesium supplement to reduce cardiac side effect risks. The research team reported an average 88% reduction in PTSD symptoms, an 87% drop in depression symptoms and an 81% reduction in anxiety symptoms one month after the ibogaine treatment. Furthermore, participants who had mild-to-moderate disabilities before treatment exhibited no disability one month after treatment, and none of the study participants had cardiac side effects.
Another study by researchers from the University of California posits that ibogaine may deliver its benefits by temporarily “reopening a critical period” where the nervous system is especially malleable. Steenkamp says that the study, which had no control group, was a “proof of concept” that proper ibogaine screening and administration could reduce the risks of deadly side effects.
The research team plans to use biomarkers and neuroimaging to learn how ibogaine works and figure out if it can provide long-term mental-health benefits.
Meanwhile, other research teams at companies such as Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) are also making headway in developing therapeutic formulations from other psychedelics, including psilocybin. The mental-health field as we know it looks set for a major transformation in the coming years.
About PsychedelicNewsWire
PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
PsychedelicNewsWire
San Francisco, CA
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicNewsWire.com
PsychedelicNewsWire is powered by IBN
This post was originally published by our media partner here.
